Drugs / RC19D2
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06047197 | Sep 2023 → Sep 2026 overdue | diffuse large B-cell lymphoma | Beijing Yongtai Ruike Biotechnology Company Ltd | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RC19D2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06047197 ↗ |
| Modality | Cell therapy | “T cells that have been genetically modified” NCT06047197 ↗ |
| Target | CD19 | “anti CD19 chimeric antigen receptors” NCT06047197 ↗ |